Table 2.

Inhibitors of epigenetic erasers

Category	Compound	Phase	Tumour type	References
Histone demethylase inhibitors
LSD1 inhibitors	Tranylcypromine	Preclinical	AML	Schenk et al., 2012
	ORY-1001	Clinical trials	Relapsed or refractory acute leukaemia	2013-002447-29
JMJC domain-containing inhibitors	8-hydroxyquinolines	Preclinical	(Enzymatic inhibition of the target protein)	King et al., 2010
	Pyridine hydrazones	Preclinical	(Enzymatic inhibition of the target protein)	Chang et al., 2011
	GSK-J1	Preclinical	(Enzymatic inhibition of the target protein)	Kruidenier et al., 2012
HDAC inhibitors
Cyclic peptides	Romidepsin	Approved	Refractory cutaneous T-cell lymphoma	Whittaker et al., 2010
Hydroxamic acids	TCA	Preclinical	Lung	Chan et al., 2013
	Vorinostat	Approved	Cutaneous T-cell lymphoma, lymphoid malignancies	Mann et al., 2007; NCT00691210
	Panobinostat	Clinical trials	Haematological malignancies, solid tumours	Cassier et al., 2014; NCT01321346
	Belinostat	Clinical trials	Ovary, colon, haematological malignancies	Plumb et al., 2003; NCT01686165
	Pracinostat	Clinical trials	Colorectal, MDS	Novotny-Diermayr et al., 2010; NCT01873703
	Quisinostat	Clinical trials	Advanced solid tumours, cutaneous T-cell lymphoma	Venugopal et al., 2013; NCT01486277
	CHR-3996	Clinical trials	Refractory solid tumours	Banerji et al., 2012; NCT00697879
Short-chain fatty acids	Phenylacetate	Clinical trials	Brain	NCT00003241
	Phenylbutirate	Clinical trials	Advanced colorectal cancer	NCT00002796
	Valproic acid	Clinical trials	Leukaemia, solid tumours	Fredly et al., 2013; Coronel et al., 2011
Benzamides	Entinostat	Clinical trials	Refractory advanced non-small cell lung cancer	Juergens et al., 2011
	Mocetinostat	Clinical trials	Haematological malignancies, advanced solid tumours	Younes et al., 2011; Siu et al., 2008
	CS055	Clinical trials	Advanced non-small cell lung cancer	NCT01836679